ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 2088 for:    Oral Cancer | NIH

Diagnostic Aids for Detection and Diagnosis of Oral Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02251639
Recruitment Status : Withdrawn (Study design improvements.)
First Posted : September 29, 2014
Last Update Posted : April 27, 2017
Sponsor:
Collaborators:
National Institutes of Health (NIH)
William Marsh Rice University
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

September 23, 2014
September 29, 2014
April 27, 2017
October 2014
October 2020   (Final data collection date for primary outcome measure)
Performance of the POS, PS2 and VELscope as Diagnostic Aid for Oral Cancer [ Time Frame: 1 day ]
Information obtained from the fluorescence and reflectance images, point spectroscopy, and oral cytology compared with clinical diagnosis to evaluate the performance of the diagnostic aids and assess any clinical benefit to assist in screening for oral cancer. ROC curve analysis used as primary method for evaluating the performance of the POS, PS2 and VELscope devices as compared to the white light standard clinical diagnosis.
Same as current
Complete list of historical versions of study NCT02251639 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Diagnostic Aids for Detection and Diagnosis of Oral Cancer
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
The goal of this clinical study is to find out if certain instruments/devices, such as wide field fluorescence imaging point spectroscopy and/or brush cytology, can help health care providers find mouth cancer more quickly than a standard oral clinical exam.

Study Procedures:

Certain types of light may cause cells to give off a tiny amount of light (called fluorescence). Researchers have learned that cancer cells and normal cells reflect light and give off fluorescence differently. Researchers want to find out if different kinds of light can be used to discover areas of the mouth that may have abnormal or cancerous cells.

If you agree to take part in this study, a researcher may use up to 3 types of imaging instruments to take pictures and readings of several areas in your mouth.

  • VELScope is an FDA approved handheld camera device that takes images of the mouth with different colors of light. The VELScope shines blue light into the mouth, and pictures are taken using a camera that is attached to the device.
  • Widefield Fluorescence Imaging uses a non-contact imaging device similar to the VELScope. It shines different colors of light and then takes pictures of the inside of the mouth using a digital camera.
  • Point Spectroscopy System uses a probe (about the size of a tip of a pen) that is gently placed on several areas of the mouth. Different colors of light are directed through optic fibers to the lining of the mouth, and the probe collects the light that returns from the tissue and sends the information to a computer.

Researchers will record whether the doctors find any areas within your mouth that may not appear completely normal. They will collect tissue samples of these abnormal areas using a brush biopsy. To perform an oral brush biopsy, the research will press a small brush against an area inside your mouth, and turn it 5-10 times. The areas that could be biopsied include your gums, tongue, the roof of your mouth, the bottom of your mouth, or the inside of your cheeks. Any cells collected from the inside of your mouth will be placed on slides to be studied by the study team.

The samples being collected will only be used for this testing, and no leftover samples will be kept by the research staff.

These procedures should take about 20 minutes total.

This is an investigational study. The VELScope is an FDA approved device and is commercially available. Wide-field and point spectroscopy systems are not FDA approved and are only authorized for research. Up to 500 participants will take part in this multicenter study. Up to 250 will be enrolled at MD Anderson.

Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Head and Neck Cancer
  • Behavioral: Questionnaire
    Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
    Other Name: Survey
  • Device: POS + PS2 + VELscope
    Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
  • Procedure: Oral Brush Biopsy
    If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
Experimental: Oral Imaging and Cytology
Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors. Oral cavity inspected using a standard white light headlamp. Oral cavity then examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device. Exfoliative cells for cytology from an abnormal area (if present) and from a contralateral normal appearing area obtained using a brush.
Interventions:
  • Behavioral: Questionnaire
  • Device: POS + PS2 + VELscope
  • Procedure: Oral Brush Biopsy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
500
October 2020
October 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subjects 18 years and older who are willing to participate.
  2. Persons presenting for: Physical or dental exams at outside health care centers OR Research meetings/gatherings OR Subjects identified at MDACC who are not already diagnosed with oral cancer or pre oral cancer: this includes patients with malignancies other than oral cancer, and visitors and family members, attendees of the HNS Oral Cancer Screening event who are willing to participate.

Exclusion Criteria:

  1. Subjects with a current diagnosis of oral cancer.
  2. Subjects under the age of 18. It is extremely unusual for children to develop oral cancer, therefore data from persons younger than 18 may add unexpected variables which could affect data analysis.
  3. Subjects who are unable or unwilling to give informed consent.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT02251639
2012-0887
NCI-2014-02105 ( Registry Identifier: NCI CTRP )
RO1 910576 ( Other Grant/Funding Number: NCI )
960113 ( Other Grant/Funding Number: CPRIT )
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Not Provided
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
  • National Institutes of Health (NIH)
  • William Marsh Rice University
Principal Investigator: Ann M. Gillenwater, MD, BA M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP